Literature DB >> 33068634

CaMKII binding to GluN2B at S1303 has no role in acute or inflammatory pain.

Uche P Maduka1, Stephanie R White2, Mei-Ling A Joiner2, Johannes W Hell3, Donna L Hammond4.   

Abstract

Activation of Ca2+/calmodulin kinase II (CaMKII) and the N-Methyl D-aspartate receptor (NMDAR), particularly its GluN2B subunit, contribute to the central sensitization of nociceptive pathways and persistent pain. Using mutant mice wherein the activity-driven binding of CaMKII to S1303 in GluN2B is abrogated (GluN2BKI), this study investigated the importance of this interaction for acute and persistent inflammatory nociception. GluN2BKI, wild type and heterozygote mice did not differ in responses to acute noxious heat stimuli as measured with tail flick, paw flick, or hot plate assays, nor did they differ in their responses to mechanical stimulation with von Frey filaments. Surprisingly, the three genotypes exhibited similar spontaneous pain behaviors and hypersensitivity to heat or mechanical stimuli induced by intraplantar injection of capsaicin; however, GluN2BKI mice did not immediately attend to the paw. WT and GluN2BKI mice also did not differ in the nociceptive behaviors elicited by intraplantar injection of formalin, even though MK801 greatly reduced these behaviors in both genotypes concordant with NMDAR dependence. CaMKII binding to GluN2B at S1303 therefore does not appear to be critical for the development of inflammatory nociception. Finally, intrathecal KN93 reduced formalin-induced nociceptive behaviors in GluN2BKI mice. KN93 does not inhibit CaKMII, but rather binds Ca2+/calmodulin. It has multiple other targets including Ca2+-, Na+- and K+-channels, as well as various kinases. Therefore, the use of GluN2BKI mice provided genetic specificity in assessing the role of CaMKII in inflammatory pain signaling cascades. These results challenge current thinking on the involvement of the CaMKII-NMDAR interaction in inflammatory pain.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CaMKII; Capsaicin; GluN2B; NMDA receptor; Nociception

Mesh:

Substances:

Year:  2020        PMID: 33068634      PMCID: PMC7719074          DOI: 10.1016/j.brainres.2020.147154

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  65 in total

Review 1.  Central sensitization and LTP: do pain and memory share similar mechanisms?

Authors:  Ru-Rong Ji; Tatsuro Kohno; Kimberly A Moore; Clifford J Woolf
Journal:  Trends Neurosci       Date:  2003-12       Impact factor: 13.837

Review 2.  The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review.

Authors:  Andrei B Petrenko; Tomohiro Yamakura; Hiroshi Baba; Koki Shimoji
Journal:  Anesth Analg       Date:  2003-10       Impact factor: 5.108

Review 3.  The use of NMDA-receptor antagonists in the treatment of chronic pain.

Authors:  D J Hewitt
Journal:  Clin J Pain       Date:  2000-06       Impact factor: 3.442

Review 4.  Evidence for spinal N-methyl-d-aspartate receptor involvement in prolonged chemical nociception in the rat.

Authors:  Jane E Haley; Anthony H Dickenson
Journal:  Brain Res       Date:  2016-02-15       Impact factor: 3.252

5.  The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca2+/CaM.

Authors:  Melanie H Wong; Alexandra B Samal; Mike Lee; Jiri Vlach; Nikolai Novikov; Anita Niedziela-Majka; Joy Y Feng; Dmitry O Koltun; Katherine M Brendza; Hyock Joo Kwon; Brian E Schultz; Roman Sakowicz; Jamil S Saad; Giuseppe A Papalia
Journal:  J Mol Biol       Date:  2019-02-10       Impact factor: 5.469

6.  Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.

Authors:  S Boyce; A Wyatt; J K Webb; R O'Donnell; G Mason; M Rigby; D Sirinathsinghji; R G Hill; N M Rupniak
Journal:  Neuropharmacology       Date:  1999-05       Impact factor: 5.250

7.  NR2B tyrosine phosphorylation modulates fear learning as well as amygdaloid synaptic plasticity.

Authors:  Takanobu Nakazawa; Shoji Komai; Ayako M Watabe; Yuji Kiyama; Masahiro Fukaya; Fumiko Arima-Yoshida; Reiko Horai; Katsuko Sudo; Kazumi Ebine; Mina Delawary; June Goto; Hisashi Umemori; Tohru Tezuka; Yoichiro Iwakura; Masahiko Watanabe; Tadashi Yamamoto; Toshiya Manabe
Journal:  EMBO J       Date:  2006-05-18       Impact factor: 11.598

8.  Perturbing PSD-95 interactions with NR2B-subtype receptors attenuates spinal nociceptive plasticity and neuropathic pain.

Authors:  Richard D'Mello; Fabien Marchand; Sophie Pezet; Stephen B McMahon; Anthony H Dickenson
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

Review 9.  CaMKII inhibitors: from research tools to therapeutic agents.

Authors:  Patricia Pellicena; Howard Schulman
Journal:  Front Pharmacol       Date:  2014-02-20       Impact factor: 5.810

10.  The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting.

Authors:  Jonathan E Tullis; Nicole L Rumian; Carolyn Nicole Brown; K Ulrich Bayer
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

View more
  1 in total

Review 1.  Roles of Phosphorylation of N-Methyl-D-Aspartate Receptor in Chronic Pain.

Authors:  Liangyu Pan; Tiansheng Li; Rui Wang; Weiheng Deng; Huangsheng Pu; Meichun Deng
Journal:  Cell Mol Neurobiol       Date:  2022-01-15       Impact factor: 5.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.